Sri Lanka FMSA Fee and Additional Data Evaluation

1. Key takeaways

The processing fee for a Manufacturing Plant approval (Foreign) in Sri Lanka is 1,500 US dollars; in addition, a separate line item exists for fees for additional data evaluation, at 500 US dollars. Converted on the April 2026 monthly fee schedule (rate 319.312 rupees per dollar), the plant approval fee corresponds to 478,968 rupees, which with 18% VAT (88,369.60 rupees) and 2.5% SSCL (11,974.20 rupees) comes to 579,311.80 rupees. The plant approval is thus the single largest fee line in the foreign entry pathway — larger than the product application itself — and the additional-data line sits beside it as a contingency that belongs in the budget from day one. Note that the table shows the converted columns for the additional data evaluation as dashes: the schedule in force at the time governs what is listed for that item, so the 500-dollar figure is the planning anchor while the rupee side is confirmed against the applicable schedule when the payment actually arises.

• Manufacturing Plant approval (Foreign): 1,500 USD, converted 478,968.00 rupees.
• With 18% VAT (88,369.60 rupees) and 2.5% SSCL (11,974.20 rupees), the total is 579,311.80 rupees.
• Additional data evaluation: 500 USD, a separate fee item.
• The converted amount for the additional-data item follows the fee schedule in force at the time.
• Conversion basis: the April 2026 schedule at 319.312 rupees per dollar.
• Plant approval follows a one-application-per-site approach.

2. Legal basis

Both fee items are published in the NMRA medical device monthly fee schedule. The table below reproduces the two lines as listed, with the April 2026 conversion for the plant approval fee.

Data source: NMRA medical device monthly fee schedule (the April 2026 schedule; conversion rate 319.312 rupees per dollar). The converted amount for the additional data evaluation follows what the fee schedule in force lists.

The 579,311.80 rupee total for a single foreign plant approval illustrates why the site dimension dominates foreign entry budgets: before a single product application is counted, the site layer already exceeds the cost of the product application by half again. For any portfolio spanning more than one site, listing the site lines first, then the product lines, then the renewal lines of later cycles, keeps the arithmetic visible and auditable at every stage of the programme.

3. Expert insights

Insight one: the plant approval fee (1,500 US dollars) is higher than the product new application fee (1,000 US dollars). This comparison shows that the review of foreign manufacturing sites is one of the most resource-intensive stages in Sri Lanka. Budgets for manufacturers with multiple sites must scale by the number of sites. A maker running three foreign plants should read the fee table as three plant-approval lines before counting any product lines at all, because the site layer of the cost structure sits underneath the product layer and multiplies independently of it.

Insight two: the additional data evaluation is a separately charged item. It means that supplementary data submitted during the review may require an additional payment. Reserving this item in the schedule and the budget avoids the passivity of seeking extra funding mid-project. Deficiency responses are not always predictable, but the possibility of one is, and a 500-dollar reservation per occurrence converts an unknown into a planned contingency that does not need fresh approval when it is drawn.

Insight three: the plant approval follows a one-application-per-site approach. Combined with the separate charging of the additional data evaluation, the fee structure for multi-product, multi-site portfolios becomes relatively complex, and it is advisable to calculate it item by item in a list. The interaction of the two dimensions — sites multiplying plant fees, products multiplying application fees, and either triggering possible evaluation fees — is exactly the kind of arithmetic that produces surprises when estimated mentally instead of tabulated. The discipline of the three-dimensional template is what turns this complexity from a risk into a checklist: every fee in the programme has a cell in the table, and every cell has a source line in the schedule it was drawn from.

4. Practical recommendations

• GRZAN’s budget template unfolds along three dimensions: product × site × cycle. The product determines the number of PRD applications and any class-based surcharges; the site determines the number of FMSA approvals and inspection fees; the cycle determines the number of renewals.
• Once the three dimensions are filled in, the full-cycle cost has a complete itemised list rather than a vague range, which is what makes the budget defensible in internal approval.
• List every product and its Class level at the start of budgeting, so the product dimension is complete before conversion begins.
• List every foreign manufacturing site, on the basis of one application per site, and count a plant approval fee of 1,500 US dollars for each.
• Reserve the additional data evaluation fee at 500 US dollars per occurrence as a contingency line, so a deficiency request never requires an unplanned payment.
• Include 18% VAT and 2.5% SSCL in every total, and convert to rupees using the monthly fee schedule in force at the time of payment.

5. Verification checklist

• □ All products and their Class levels have been listed
• □ All foreign manufacturing sites have been listed (one application per site)
• □ The plant approval fee has been included (Foreign: 1,500 US dollars)
• □ The additional data evaluation fee has been reserved (500 US dollars per occurrence)
• □ 18% VAT and 2.5% SSCL have been included
• □ Conversion to rupees has been performed on the current monthly fee schedule

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including Sri Lanka. Our team prepares dossiers to NMRA expectations, manages submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com

Regulatory information verified as of 28 October 2026.